Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;33(10):2540-2544.
doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

Tania Jain  1 , Craig S Sauter  1   2 , Gunjan L Shah  1   2 , Molly A Maloy  1 , Jason Chan  1 , Michael Scordo  1   2 , Scott T Avecilla  3 , Yakup Batlevi  1 , Parastoo B Dahi  1   2 , Connie W Batlevi  2   4 , M Lia Palomba  2   4 , Sergio A Giralt  1   2 , Miguel-Angel Perales  5   6
Affiliations

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

Tania Jain et al. Leukemia. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures:

Tania Jain – No conflict of interest

Craig Sauter - Consultant on advisory boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences, Kite, a Gilead Company and GSK. Research funds for investigator-initiated trials from: Juno Therapeutics and Sanofi-Genzyme.

Gunjan Shah - Research funding from Janssen and Amgen

Molly Maloy – No conflict of interest

Jason Chan – No conflict of interest

Michael Scordo – Consultancy: Angiocrine Bioscience, Inc., McKinsey & Company

Scott Avecilla - Honoraria for presenting a project in partnership with Abbott Laboratories

Yakup Batlevi – No conflict of interest

Parastoo Dahi – No conflict of interest

Connie Batlevi – Research funding from Epizyme, Novartis, Janssen, BMS, Miragen, Mediimmune; Consultancy from Defined Health, GLG, Guidepoint Global; Honoraria from Dava Oncology

M Lia Palomba – Advisory Board for Celgene, Consultant for Merck and Pharmacyclics

Sergio Giralt – Advisory Board for Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma; Research funding from Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda

Miguel-Angel Perales - Honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. Research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec.

Figures

Figure 1:
Figure 1:. Timeline of events for all patients
CGVHD, chronic graft versus host disease; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; CY, cyclophosphamide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; Gem, gemcitabine; GVHD, graft versus host disease; lb, ibrutinib; ICE, ifosfamide, carboplatin and etoposide; IS, immunosuppression therapy; L, lenalidomide; Liso, Lisocabtagene Maraleucel; M, methotrexate; Ox, oxaliplatin; PR, partial response; PD, progressive disease; R, rituximab; Th, Thiotepa; XRT, radiation therapy
See this image and copyright information in PMC

References

    1. Perales MA, Kebriaei P, Kean LS, Sadelain M. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant 2018. January; 24(1): 27–31. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017. December 28; 377(26): 2531–2544. - PMC - PubMed
    1. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 2017. December 28; 377(26): 2545–2554. - PMC - PubMed
    1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 2018. December 25. - PubMed
    1. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol 2016. April 1; 34(10): 1112–1121. - PMC - PubMed

Publication types

Substances